Document is current
Any future updates will be listed below
-
Authors
Schnabel, Dirk http://orcid.org/0000-0002-7944-7790
Kreitschmann-Andermahr, Ilonka
Strasburger, Christian J.
Pittrow, David
Pausch, Christine
Woelfle, Joachim
,
-
Funding
Funding for this research was provided by:
Sandoz
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 20 February 2023
Accepted: 30 April 2023
First Online: 10 May 2023
Declarations
:
: The registry materials (protocol, patient information and informed consent form (ICF), and other required documents) were approved by the primary ethics committee (Ethics Committee of the Physician Chamber Saxony EK-BR-8/22-1 dated 26 January 2022). Any site that joins the registry has to provide additional ethics approval, if required by their local institutions. Protocol amendments, if any, will be subject to the same requirements as the original protocol. Written informed consent is a prerequisite for patients to be eligible for documentation in the study.
: Not applicable. The manuscript does not contain any individual person’s data in any form.
: DS: received consultant and/or speaker fees from Ascendis, Biomarin, Kyowa Kirin, Merck/Serono, Novo Nordisk, Pfizer, Sandoz/Novartis. CS: received consultancy fees from NovoNordisk, Sandoz-Hexal/Novartis, Ascendis, Pfizer, Consilient Health, Crinetics and Ipsen. DP: received consultancy fees from Amgen, Aspen, Biogen, Daiichi Sankyo, Sanofi-Genzyme, Sandoz/Novartis, MSD and Zambon. CP: has no competing interests. JW: received consultant and/or speaker fees from Ascendis, Biomarin, Merck/Serono, Novo Nordisk, Pfizer, Sandoz/Novartis. IKA: received consultant and speaker fees from Sandoz/Novartis and Pfizer.
